|Jump to:||Authorized Access|||||Attribution|||||Authorized Requests|
- Study Description
As part of the TARGET initiative, some disease projects characterized tumor cell lines or xenografts, with or without matched normal comparators, as well as some normal non-involved tissues. These reagents will be available for in vitro validation experiments and their molecular characteristics will be available through the TARGET Data Matrix. MDLS includes acute leukemia cell lines and xenografts with matched primary and/or relapsed tumor information, neuroblastoma cell line and xenografts with matched controls, kidney tumor cell lines, normal brain tissues and embryonic stem cell lines. Additionally, in partnership with TARGET, 131 cell lines and xenografts from the NCI's Pediatric Preclinical Testing Program Pediatric Preclinical Testing Program will receive next generation sequencing of the whole exome, and will have associated expression and copy number data available through the TARGET Data Matrix once generated. Please visit the TARGET website, http://ocg.cancer.gov/programs/target, for additional information on this and other TARGET genomics projects. Please see the TARGET Publication Guidelines at the OCG website for updated details on sharing of any TARGET substudy data.
- Study Weblinks:
- Study Design:
- Tumor vs. Matched-Normal
- Study Type:
- Number of study subjects that have individual-level data available through Authorized Access:
- Authorized Access
- Publicly Available Data (Public ftp)
- Study Inclusion/Exclusion Criteria
Data is currently being generated for this substudy.
- Study History
Pediatric ALL and neuroblastoma were the first diseases to be piloted for the TARGET initiative, and ARRA funding allowed for its expansion to include pediatric AML, as well as osteosarcoma and kidney cancers. TARGET is jointly managed by the NCI Office of Cancer Genomics (OCG) and Cancer Therapy Evaluation Program (CTEP). The TARGET initiative is run as a cooperative collaboration between investigators and management staff at NCI, Children's Oncology Group, and multiple elite children's research hospitals and cancers centers throughout North and South America.
May, 2005 NCI and the American Cancer Society co-sponsor "Childhood Cancer Targeted Therapeutics Workshop" that ultimately served as a basis for the conception of TARGET. October, 2006 TARGET project officially initiated. January, 2009 First publication of characterization and analysis of 221 pediatric ALL patients from the pilot phase of TARGET. September, 2009 ARRA funding allows for expansion of TARGET pilot project to include additional cancers of study.
- Selected publications
- Diseases/Traits Related to Study (MeSH terms)
- Primary Phenotype: Antitumor Assay, Xenograft
- Links to Related Resources
- Authorized Data Access Requests
- Study Attribution